Patient-Derived Cell-Free Scaffolds for Tumor Microenvironment Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods face challenges such as therapy resistance, over-treatment due to lack of predictive information, and inefficiencies in targeting cancer cells, particularly in modulating the immune response and understanding tumor microenvironments.
Innovation Solution
Patient-derived cell-free scaffolds are used to create in vitro models that mimic the tumor microenvironment, allowing for the selection and culture of cancer cells to analyze immunomarkers and determine tumor properties, susceptibility to immunotherapy, and assess treatment efficacy, thereby providing patient-specific information for personalized cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If patient-derived cell-free scaffolds are used to create in vitro models, then measurement precision of tumor properties and treatment prediction is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent extracts the essential tumor microenvironment components by creating cell-free scaffolds from patient-derived tumors. The scaffolds are decellularized to remove cellular material while preserving the extracellular matrix structure, thereby isolating the critical architectural and biochemical cues needed for accurate cancer cell culture without the complexity of living tissue
Solution Approach 2:
The patent creates accurate copies of the tumor microenvironment by fabricating scaffolds that replicate the native extracellular matrix structure, composition, and biochemical signals. These scaffold copies enable in vitro models to mimic in vivo tumor conditions, providing precise treatment predictions without requiring actual tumor tissue
2Measurement precision
If patient-specific scaffolds are used for personalized therapy assessment, then treatment prediction accuracy is improved, but loss of time for model creation and productivity decrease
Solution Approach 1:
The patent performs preliminary actions by preparing patient-specific scaffolds in advance from tumor samples obtained during routine diagnostics. The scaffolds are pre-characterized with respect to their extracellular matrix composition and biochemical properties, enabling rapid cell culture setup and treatment assessment without delaying clinical decision-making
Solution Approach 2:
The patent optimizes culture parameters such as scaffold processing conditions, cell seeding densities, and incubation times to reduce model creation time. By adjusting these parameters, the system achieves accurate treatment predictions within clinically relevant timeframes, balancing precision with productivity
3Loss of information
If cancer cells are cultured in patient-derived scaffolds to analyze immunomarkers, then information on immune response is improved, but quantity of substance and cost increase
Solution Approach 1:
The patent segments the complex tumor microenvironment into discrete, analyzable components by culturing cancer cells in patient-specific scaffolds. This segmentation allows for targeted analysis of specific immunomarkers and immune cell interactions, extracting maximum information from minimal amounts of patient-derived material
Data Source
AI summary
Cell-free scaffolds derived from tumors in patients are used as in vitro cancer models and also provide information of the tumor, from which it is derived, including its susceptibility to cancer treatment. The cell-free scaffolds are also used as a predictive tool in assessing cancer treatment efficacy and in identifying immunotargets and biomarkers for cancer therapy.